FILING ANALYSIS · TUESDAY, NOVEMBER 10
Opus Genetics, Inc. IRD — 8-K: Results of Operations and Financial Condition
neutral
Opus Genetics announced positive results from its Phase 1/2 trial of OPGx-BEST1 and provided a corporate update, including full enrollment of its registrational Phase 3 trial for OPGx-LCA5 and FDA clearance of the IND for OPGx-RDH12, with a cash runway into 2029. However, there are no significant quantified surprises in the announcement that would likely move the stock beyond 1.5% in a week.
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →